ENDOSCOPIC AND CLINICAL EFFICACY DEMONSTRATED WITH ORAL OZANIMOD IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Brian G. Feagan  ¹     William Sandborn  ²     Geert R. D'Haens  ³     Barrett G. Levesque  ¹     Brett E. Skolnick  ⁴     Caiyan Li  ⁵     Darryl Penenberg     Richard Aranda     Allan Olson    
¹ Robarts Research Institute,London,Canada
² University of California,Division of Gastroenterology,La Jolla, San Diego,United States of America
³ Academic Medical Center,Amsterdam,Netherlands
⁴ Receptos, a wholly owned subsidiary of Celgene,San Diego,United States of America
⁵ Receptos, a wholly-own

Conference
25th UEG Week 2017

Citation
United European Gastroenterology Journal 2017; 5 (Supplement 1)